Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study
Authors
Keywords
-
Journal
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Volume 15, Issue 10, Pages 2017-2028
Publisher
Wiley
Online
2017-08-14
DOI
10.1111/jth.13801
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays
- (2016) R. Gosselin et al. International Journal of Laboratory Hematology
- The laboratory's 2015 perspective on direct oral anticoagulant testing
- (2016) R. C. Gosselin et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence
- (2015) B. Vrijens et al. EUROPACE
- Novel Anticoagulants in Atrial Fibrillation: A Primer for the Primary Physician
- (2015) M. Mookadam et al. Journal of the American Board of Family Medicine
- Normal prothrombin times in the presence of therapeutic levels of apixaban -in-vivoexperience from King's College Hospital
- (2014) Jignesh P. Patel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
- (2013) Wolfgang Mueck et al. CLINICAL PHARMACOKINETICS
- European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
- (2013) Hein Heidbuchel et al. EUROPACE
- Novel anticoagulants and laboratory testing
- (2013) C. Eby International Journal of Laboratory Hematology
- Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
- (2013) T. Baglin et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban
- (2013) Reinhold Kreutz JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- The new oral anticoagulants in atrial fibrillation: Once daily or twice daily?
- (2013) Giulia Renda et al. VASCULAR PHARMACOLOGY
- Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
- (2012) Charles Frost et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of dosing frequency on chronic cardiovascular disease medication adherence
- (2012) Craig I. Coleman et al. CURRENT MEDICAL RESEARCH AND OPINION
- Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation
- (2012) Jeanne Mendell et al. THROMBOSIS AND HAEMOSTASIS
- Molecular Basis of Chronopharmaceutics
- (2011) Shigehiro Ohdo et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- The Role of Clock Genes in Pharmacology
- (2010) Georgios K. Paschos et al. Annual Review of Pharmacology and Toxicology
- Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation
- (2010) Stuart Connolly et al. THROMBOSIS AND HAEMOSTASIS
- Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
- (2010) Jean-Luc Martinoli et al. THROMBOSIS AND HAEMOSTASIS
- Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects
- (2008) Dagmar Kubitza et al. CURRENT MEDICAL RESEARCH AND OPINION
- The influence of circadian rhythms on the kinetics of drugs in humans
- (2008) Massimo Baraldo Expert Opinion on Drug Metabolism & Toxicology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search